Tuesday, 13 April 2021


Aurobindo diabetes generic gets US FDA nod

04 February 2014 | Regulatory | By BioSpectrum Bureau

Good news for diabetes patients - Aurobindo generic gets US FDA nod

Good news for diabetes patients - Aurobindo generic gets US FDA nod

Singapore: Aurobindo Pharma has received US FDA approval for Repaglinide tablets, the generic equivalent of Novo Nordisk's Prandin Tablets.

The drug is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

The market size of the product is estimated to be $274 million for the 12 months ending November 2013, according to IMS Health.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account